COVID-19 breakthrough infections in rheumatic diseases patients after vaccination.

ABSTRACT:

Background

Rheumatic diseases patients receiving Rituximab had severe COVID-19 disease. Although they had impaired humoral immune responses following COVID-19 vaccine, they had preserved cellular immune responses. Waning of COVID-19 antibody responses was observed within six months post vaccination among immunocompromised patients. Recent reports showed fatal outcome of breakthrough SARS-CoV-2 infections among vaccinated high-risk rheumatic diseases patients receiving Rituximab. SAR-CoV-2 serological tests were not performed.

Objective

Evaluation of COVID-19 vaccine humoral responses and breakthrough infections among low risk fully vaccinated rheumatic patients during the Delta Variant Era.

Methods

A case series of 19 fully vaccinated patients with rheumatic diseases

SUBMITTER: Alshukairi AN 

PROVIDER: S-EPMC9098803 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature